D&D Pharmatech Inc. (KOSDAQ:347850)

South Korea flag South Korea · Delayed Price · Currency is KRW
145,200
+2,700 (1.89%)
Aug 14, 2025, 2:40 PM KST
342.01%
Market Cap 1.54T
Revenue (ttm) 10.75B
Net Income (ttm) -32.98B
Shares Out 10.82M
EPS (ttm) -3,151.24
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 221,189
Average Volume 220,367
Open 142,000
Previous Close 142,500
Day's Range 140,600 - 147,400
52-Week Range 28,300 - 157,200
Beta n/a
RSI 60.10
Earnings Date Aug 12, 2025

About D&D Pharmatech

D&D Pharmatech Inc., a clinical-stage biotech company, develops medicines in South Korea and the United States. It develops NLY01-PD, NLY01-AD, and NLY01-D that are in Phase II clinical trials for the treatment of Parkinson’s disease (PD), Alzheimer’s disease (AD), and type 2 diabetes; and P4M01, which has completed Phase IIa clinical trials to treat periodontal disease. The company also develops DD01 that is in Phase I clinical trials for the treatment of obesity/diabetes/nonalcoholic steatohepatitis (NASH); TLY012, which is Phase I clinical t... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 347850
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.